Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Lieberman

Showing results (21-30 of 64) with videos related to

Pageof 7
Sort By:
Psychiatry (Edgmont (Pa. : Township))|September 1, 2010
Use of Antipsychotics Pre- and Post-Dissemination of CATIE DataElisa F Cascade, Amir H Kalali, Jeffrey Lieberman, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|March 3, 2006
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophreniaPeter Falkai, Thomas Wobrock, Jeffrey Lieberman, et al.
The International Journal of Neuropsychopharmacology|April 4, 2001
Effects of risperidone on auditory event-related potentials in schizophreniaDaniel Umbricht, Daniel Javitt, Gerald Novak, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|June 24, 2010
Characterization of in vivo pharmacokinetic properties of the dopamine D1 receptor agonist DAR-0100A in nonhuman primates using PET with [11C] NNC112 and [11C] racloprideMark Slifstein, Raymond F Suckow, Jonathan A Javitch, et al.
Schizophrenia Research|February 12, 2008
Association of RGS2 and RGS5 variants with schizophrenia symptom severityDaniel B Campbell, Leslie A Lange, Tara Skelly, et al.
Schizophrenia Research|November 11, 2008
Does switching to a new antipsychotic improve outcomes? Data from the CATIE TrialRobert A Rosenheck, Sonia Davis, Nancy Covell, et al.
Schizophrenia Research|October 22, 2008
A systematic method for estimating individual responses to treatment with antipsychotics in CATIEEdwin J C G van den Oord, Daniel E Adkins, Joseph McClay, et al.
Schizophrenia Research|June 24, 2009
Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trialRobert A Rosenheck, Vicki G Davis, Sonia M Davis, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|March 31, 2015
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactationAlkomiet Hasan, Peter Falkai, Thomas Wobrock, et al.
International Journal of Psychiatry in Clinical Practice|May 13, 2017
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia - a short version for primary careAlkomiet Hasan, Peter Falkai, Thomas Wobrock, et al.
Pageof 7

Showing results (21-30 of 64) with videos related to

Sort By:
Pageof 7
Psychiatry (Edgmont (Pa. : Township))|September 1, 2010
Use of Antipsychotics Pre- and Post-Dissemination of CATIE DataElisa F Cascade, Amir H Kalali, Jeffrey Lieberman, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|March 3, 2006
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophreniaPeter Falkai, Thomas Wobrock, Jeffrey Lieberman, et al.
The International Journal of Neuropsychopharmacology|April 4, 2001
Effects of risperidone on auditory event-related potentials in schizophreniaDaniel Umbricht, Daniel Javitt, Gerald Novak, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|June 24, 2010
Characterization of in vivo pharmacokinetic properties of the dopamine D1 receptor agonist DAR-0100A in nonhuman primates using PET with [11C] NNC112 and [11C] racloprideMark Slifstein, Raymond F Suckow, Jonathan A Javitch, et al.
Schizophrenia Research|February 12, 2008
Association of RGS2 and RGS5 variants with schizophrenia symptom severityDaniel B Campbell, Leslie A Lange, Tara Skelly, et al.
Schizophrenia Research|November 11, 2008
Does switching to a new antipsychotic improve outcomes? Data from the CATIE TrialRobert A Rosenheck, Sonia Davis, Nancy Covell, et al.
Schizophrenia Research|October 22, 2008
A systematic method for estimating individual responses to treatment with antipsychotics in CATIEEdwin J C G van den Oord, Daniel E Adkins, Joseph McClay, et al.
Schizophrenia Research|June 24, 2009
Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trialRobert A Rosenheck, Vicki G Davis, Sonia M Davis, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|March 31, 2015
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactationAlkomiet Hasan, Peter Falkai, Thomas Wobrock, et al.
International Journal of Psychiatry in Clinical Practice|May 13, 2017
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia - a short version for primary careAlkomiet Hasan, Peter Falkai, Thomas Wobrock, et al.
Pageof 7